Latest News
Stay informed on developments in peptide research, emerging compounds, clinical research and the Australian regulatory landscape.
Explore Our Research Collection
Browse our complete range of research materials.
Retatrutide Advances Through Phase 3 Research
Retatrutide continues to be one of the most closely followed investigational peptide compounds. In 2026, Eli Lilly reported positive topline results from additional Phase 3 trials studying retatrutide in adults with obesity or overweight and type 2 diabetes, as well as adults with severe obesity and cardiovascular disease. Lilly has stated that it plans to submit retatrutide to the FDA for review in the first quarter of 2027.
Source: Eli Lilly — July 2026TGA Takes Further Action Against Unapproved Peptide Products
Australia's Therapeutic Goods Administration has continued increasing enforcement activity around unapproved peptide products. In August 2026, the TGA announced a seizure of more than $120,000 worth of illicit peptide and anabolic steroid products following an operation conducted with NSW Police. The products reportedly included retatrutide and CJC-1295.
Source: Therapeutic Goods AdministrationTGA Warns Peptide Suppliers and Promoters
The TGA has warned businesses and individuals involved in the unlawful advertising, importing, manufacturing or supply of unapproved peptide products. The regulator has highlighted potential legal consequences and stated that compliance activity in this area is continuing.
Source: Therapeutic Goods AdministrationUnapproved Peptides Become a TGA Compliance Priority
The TGA expanded its priority compliance focus to include unapproved peptide products following increased detection of unlawful importation, supply and advertising. The regulator said the change reflects an evolving market and growing concerns surrounding consumer safety.
Source: Therapeutic Goods AdministrationTGA Highlights Risks Associated With Unapproved Peptides
Australian health authorities issued a joint statement warning about the growing availability, promotion and use of unapproved peptide products. The statement noted reports of serious adverse effects associated with some unapproved products and stressed that products not included in the Australian Register of Therapeutic Goods have not been evaluated by the TGA for safety, quality or effectiveness.
Source: Therapeutic Goods AdministrationNew Safety Information for GLP-1 Receptor Agonists
The TGA updated product warnings for the GLP-1 receptor agonist class in July 2026 following safety information concerning a rare but serious eye disorder. The update applies to prescription medicines in the GLP-1 receptor agonist class marketed in Australia.
Source: Therapeutic Goods AdministrationPeptide Research Continues to Expand
Peptide research continues across areas including metabolic science, endocrinology, cellular signalling and other areas of biomedical research. Investigational compounds are being evaluated through laboratory studies and clinical trials to better understand their mechanisms, biological activity, safety and potential applications.
Research & scientific literatureExplore Our Collection
Browse our complete range of research materials.